For the past few years, it’s been nearly impossible to talk about diabetes without talking about GLP-1s.

Medications like Ozempic, Wegovy, Mounjaro, and Zepbound have become household names, changing the way doctors approach Type 2 diabetes and obesity. But increasingly, another group is entering the conversation: people with Type 1 diabetes.

Insulin remains essential for anyone with Type 1. GLP-1 medications can’t replace it, and they aren’t currently approved specifically to treat Type 1 diabetes.

Still, researchers are asking an interesting question: could GLP-1s eventually have a supporting role alongside insulin?

Early studies suggest there may be potential, particularly for people with Type 1 diabetes. But there are important risks and plenty of unanswered questions, too.

Here’s where the research stands today and where it might be headed next.

First, What Exactly Is a GLP-1?

GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally releases after you eat.

Among other things, GLP-1 helps regulate appetite, slows how quickly food leaves the stomach, influences glucagon secretion, and helps the body release insulin in response to glucose.

GLP-1 receptor agonists mimic some of those effects. Newer medications may target more than one hormone pathway. Tirzepatide, for example, acts on both GLP-1 and GIP receptors.

For people with Type 2 diabetes, these medications can improve glucose management while also helping some people lose weight. Certain GLP-1–based medications have also demonstrated cardiovascular, kidney, and other health benefits in specific populations.

Type 1 diabetes is different.

People with Type 1 produce little or no insulin because the immune system has attacked the insulin-producing beta cells in the pancreas. No matter how effective another medication becomes, insulin remains necessary.

So why are GLP-1s entering the Type 1 conversation at all?

Type 1 Diabetes Doesn’t Rule Out Insulin Resistance

There’s a common misconception that insulin resistance belongs exclusively to Type 2 diabetes.

It doesn’t.

Someone with Type 1 diabetes can also develop insulin resistance, and people with Type 1 can live with obesity just like anyone else. In those cases, managing Type 1 can involve both replacing the insulin the body no longer produces and navigating a body that may require more insulin to achieve the same effect.

That can create a frustrating cycle. Higher insulin requirements can make glucose management more complicated, while weight, appetite, activity, hormones, genetics, and many other factors can influence insulin sensitivity.

This overlap is one reason researchers have become increasingly interested in GLP-1–based medications for some people with Type 1.

What Are Researchers Seeing So Far?

One of the most interesting recent studies looked at semaglutide used alongside an automated insulin delivery system in adults with Type 1 diabetes.

In the randomized crossover trial, participants spent an average of 4.8 percentage points more time in the target glucose range while taking semaglutide compared with placebo. Their insulin requirements also decreased, without an increase in time spent in hypoglycemia.

That doesn’t mean semaglutide has been proven appropriate for everyone with Type 1. The study was small, with 28 participants randomized and 24 completing the trial.

But it provided something researchers have been looking for: controlled evidence that a GLP-1 medication may affect more than weight when used alongside modern Type 1 diabetes technology.

Why it matters:

The future of Type 1 treatment may not be about asking insulin to do everything.

Insulin will always be essential unless a therapy restores or replaces the body’s ability to produce it. But adjunctive medications could potentially address other pieces of the metabolic picture, including insulin resistance, appetite, weight, and post-meal glucose.

Could GLP-1s and Automated Insulin Delivery Work Together?

This may be one of the most interesting areas to watch.

Today’s automated insulin delivery systems are remarkably sophisticated, but they still have to respond to variables that insulin alone can’t control.

Meals are a perfect example.

Even with a fast-acting insulin bolus, injected insulin doesn’t perfectly recreate the speed and timing of insulin released by a functioning pancreas. Large meals, high-fat foods, delayed digestion, and missed or late boluses can all give an algorithm a lot to contend with.

GLP-1 medications slow gastric emptying and can reduce appetite and food intake. They can also substantially change a person’s insulin requirements.

That creates the possibility of GLP-1 therapy and AID complementing one another, but it also means the two need to be studied carefully together.

As insulin needs change, pump settings and automated insulin delivery may need to change with them.

Researchers are now investigating what that combination looks like in practice.

Weight Is Part of the Conversation, But It Isn’t the Whole Conversation

It would be impossible to discuss GLP-1s without acknowledging weight. Much of the public attention surrounding these medications has focused on weight loss, and obesity is one reason someone with Type 1 may already be prescribed a GLP-1–based medication.

But reducing the entire Type 1 conversation to weight misses some of what researchers are studying.

Recent trials have looked at time in range, insulin requirements, glucose management, and how GLP-1 medications interact with automated insulin delivery.

In a 2026 analysis of adults with Type 1 diabetes and obesity using AID, participants taking semaglutide needed substantially less insulin by the end of the 26-week study.

That raises questions that go well beyond the number on a scale.

Could some people achieve the same or better glucose outcomes while requiring less insulin? Could GLP-1 therapy help address insulin resistance in Type 1? Could it eventually make automated systems more effective or reduce some of the work required around meals?

Those are much more interesting questions than simply whether someone loses weight.

There Are Important Risks

The excitement around GLP-1s in Type 1 diabetes comes with an important caveat: reducing insulin too aggressively can be dangerous.

People with Type 1 need insulin even when they’re eating less.

If nausea, reduced appetite, or weight loss leads someone to dramatically decrease insulin, ketones can begin to accumulate. And because GLP-1 medications can reduce food intake and glucose levels, ketosis or DKA may not always arrive alongside the extremely high blood sugar someone might expect.

In the semaglutide crossover trial, researchers reported no DKA or severe hypoglycemia, but there were two episodes of recurrent euglycemic ketosis without acidosis while participants were taking semaglutide.

Gastrointestinal side effects such as nausea and vomiting can complicate things further because those symptoms can overlap with warning signs of ketosis and DKA.

The ADA’s 2026 Standards also note that factors including recent DKA or euglycemic ketoacidosis, hypoglycemia unawareness, and gastroparesis may make GLP-1–based therapy inappropriate for some people with Type 1 diabetes and obesity.

Why it matters:

Taking less insulin isn’t automatically better.

For someone with Type 1 diabetes, insulin isn’t simply a medication used to lower blood sugar. The body needs it to prevent ketosis.

Any future role for GLP-1s in Type 1 will need to account for that reality, including clear guidance around insulin adjustments, ketone monitoring, illness, and what to do when someone can’t eat normally.

So, Are GLP-1s Approved for Type 1 Diabetes?

Not as a treatment for Type 1 diabetes itself.

Some people with Type 1 may be prescribed a GLP-1–based medication for another approved indication, such as obesity, but that’s different from the medication being approved to treat Type 1 diabetes.

That distinction matters because the evidence base, dosing strategies, insulin adjustments, and safety guidance for Type 1 are still developing.

It also means this isn’t a medication someone with Type 1 should simply add to their existing routine without working closely with a healthcare professional who understands insulin management.

What Happens Next?

This is where things get interesting.

The ADA’s 2026 Standards now specifically address GLP-1–based medications in people with Type 1 diabetes and obesity, including considerations for their use alongside automated insulin delivery.

Meanwhile, researchers continue to study how these medications affect insulin needs, time in range, weight, and the day-to-day experience of managing Type 1.

The unanswered questions are just as important.

Which people with Type 1 are most likely to benefit? How should insulin doses and AID settings change when treatment begins? How do we minimize ketosis risk? Do the benefits continue long term? And could future automated systems eventually account for the metabolic effects of these medications more directly?

We don’t have all of those answers yet.

Final Thoughts

GLP-1s have already changed the treatment landscape for Type 2 diabetes and obesity. Their role in Type 1 diabetes is much less established, but it’s becoming increasingly difficult to dismiss the conversation as simply off-label experimentation.

We now have randomized trials, growing real-world use, and new guidance acknowledging that some people with Type 1 may benefit from GLP-1–based medications for obesity.

What comes next will depend on larger and longer studies that can show not only whether these medications improve certain outcomes, but who benefits, how they can be used safely, and how they fit alongside increasingly sophisticated diabetes technology.

For now, insulin remains at the center of Type 1 diabetes treatment.

But the future may include more tools working alongside it.